Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Liwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-0234-8282; OpenAlex author ID A5100406722. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 4 papers · 2016: 7 papers · 2017: 4 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 28

  1. Discovering signature disease trajectories in pancreatic cancer and soft-tissue sarcoma from longitudinal patient records. Co-author DOI 10.1016/j.jbi.2025.104935↗
  2. The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Last author DOI 10.1007/s00262-024-03644-2↗
  3. Correction to: The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Last author DOI 10.1007/s00262-024-03739-w↗
  4. Cuproptosis-related lncRNAs are correlated with metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients Last author DOI 10.21203/rs.3.rs-1645540/v1↗
  5. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Last author DOI 10.3389/fcell.2022.1001606↗
  6. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Last author DOI 10.3389/fcell.2022.942225↗
  7. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Last author DOI 10.1038/s41598-017-00288-4↗
  8. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Last author DOI 10.1038/s41598-017-03153-6↗
  9. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancrea… Last author DOI 10.18632/oncotarget.14069↗
  10. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Last author DOI 10.18632/oncotarget.16633↗
  11. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Last author DOI 10.1007/s13277-015-4741-z↗
  12. Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13277-016-5457-4↗
  13. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. Last author DOI 10.18632/oncotarget.12447↗
  14. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic ca… Last author DOI 10.18632/oncotarget.7156↗
  15. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Last author DOI 10.18632/oncotarget.7663↗
  16. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.8593↗
  17. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  18. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Last author DOI 10.1007/s00432-015-1953-y↗
  19. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Last author DOI 10.1007/s12032-015-0589-8↗
  20. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/srep10081↗
  21. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Last author DOI 10.1159/000369686↗
  22. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Co-author DOI 10.3892/ijo.2014.2568↗
  23. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-3859↗
  24. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer… Last author DOI 10.7314/apjcp.2013.14.12.7529↗
  25. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Co-author DOI 10.1158/0008-5472.can-11-3102↗
  26. Sp/KLF family and tumor angiogenesis in pancreatic cancer. Last author DOI 10.2174/13816128112092420↗
  27. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Co-author DOI 10.2174/13816128112092464↗
  28. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Co-author DOI 10.1158/0008-5472.can-10-2016↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 11 shared papers, 2012–2022 · strength 0.86
  2. Shengbai Xue · 5 shared papers, 2022–2024 · strength 0.84
  3. Yanling Wang · 4 shared papers, 2022–2024 · strength 0.67
  4. Feng Jiao · 9 shared papers, 2014–2017 · strength 0.57
  5. Hai Xia Hu · 9 shared papers, 2014–2017 · strength 0.55
  6. Ting Han · 7 shared papers, 2016–2017 · strength 0.47
  7. Lei Wang · 7 shared papers, 2014–2017 · strength 0.45
  8. Xiaofei Zhang · 3 shared papers, 2022 · strength 0.44
  9. Weiyu Ge · 3 shared papers, 2022 · strength 0.44
  10. Meng Zhuo · 6 shared papers, 2016–2017 · strength 0.41
  11. Qing Xia · 2 shared papers, 2024 · strength 0.40
  12. Wenxin Lu · 2 shared papers, 2024 · strength 0.40
  13. Tiebo Mao · 2 shared papers, 2022 · strength 0.26
  14. Jiayu Yao · 2 shared papers, 2022 · strength 0.26
  15. Junjie Hang · 4 shared papers, 2016–2017 · strength 0.26
  16. Weifeng Song · 4 shared papers, 2013–2016 · strength 0.24
  17. Haiyan Yang · 4 shared papers, 2015–2017 · strength 0.24
  18. Matthew H. G. Katz · 1 shared paper, 2025 · strength 0.23
  19. Adriana Carolina Gamboa · 1 shared paper, 2025 · strength 0.23
  20. Hongfang Liu · 1 shared paper, 2025 · strength 0.23
  21. Christina Lynn Roland · 1 shared paper, 2025 · strength 0.23
  22. Weiyi Huang · 4 shared papers, 2013–2017 · strength 0.23
  23. Yu Wang · 1 shared paper, 2024 · strength 0.20
  24. Yanling Wang · 1 shared paper, 2022 · strength 0.17
  25. Leilei Wu · 2 shared papers, 2017 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.